Serum neuregulin -1 (NRG-1) is a potential biomarker for early diagnosis and prediction in refractory schizophrenia
<p>This study tends to identify serum biomarkers for early diagnosis of treatment-resistant schizophrenia (TRS) and prediction of clozapine treatment response, given the heterogeneity of schizophrenia and limitations of antipsychotic treatment.</p> <p>Participants of this prospecti...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Další autoři: | |
| Vydáno: |
2025
|
| Témata: | |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | <p>This study tends to identify serum biomarkers for early diagnosis of treatment-resistant schizophrenia (TRS) and prediction of clozapine treatment response, given the heterogeneity of schizophrenia and limitations of antipsychotic treatment.</p> <p>Participants of this prospective cohort study (recruited at Shanghai Mental Health Center; 2020–2023) included 42 TRS patients (TRRIP criteria), 42 first-line antipsychotic responders (age/sex-matched 1:1 to TRS), and 70 age/sex-matched healthy controls. TRS patients were stratified post-clozapine into responders (TRS-R, <i>n</i> = 26) and ultra-treatment-resistant (UTRS, <i>n</i> = 16) subgroups. Symptom severity was assessed using PANSS. Serum neuregulin-1 (NRG-1) levels were quantified via ELISA.</p> <p>Healthy controls showed significantly higher NRG-1 levels than schizophrenia patients (F = 39.76, <i>p</i> < 0.001). TRS patients had lower NRG-1 than treatment responders (<i>p</i> < 0.001). Clozapine responders (TRS-R) exhibited increased NRG-1 post-treatment (<i>t</i> = −3.32, <i>p</i> < 0.001), unlike UTRS patients (<i>t</i> = −0.332, <i>p</i> = 0.745). NRG-1 negatively correlated with symptom severity in both TRS (<i>r</i> = −0.647, <i>p</i> < 0.001) and responders (<i>r</i> = −0.596, <i>p</i> < 0.001). NRG-1 demonstrated diagnostic utility for TRS (AUC = 0.827, 95% CI:0.741–0.914; specificity = 0.786, sensitivity = 0.786).</p> <p>Serum NRG-1 shows significant promise as a potential biomarker for diagnosing TRS and monitoring clozapine treatment response, suggesting involvement in TRS pathophysiology.</p> |
|---|